Loading…
Employees: 2,914
Size Brother Enterprises (002562.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $716M, the 3017th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.20 on 6 Nov 2026.
Performance Over six months the shares fell 28.4%, against -17.2% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 7.8% over the last twelve months (peer median -4.2%); the operating margin is 4.0% (peer median 9.5%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 3.4× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points below its cost of capital (6.9% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.85B | CN¥3.61B | CN¥3.44B | CN¥2.82B | CN¥3.41B |
| Revenue growth | — | +5% | +22% | -17% | — |
| Gross profit | CN¥894M | CN¥542M | CN¥464M | CN¥253M | CN¥810M |
| EBITDA | n/a | CN¥550M | CN¥440M | CN¥187M | CN¥699M |
| Net income | CN¥109M | CN¥95.1M | CN¥40.8M | -CN¥175M | CN¥306M |
| Free cash flow | CN¥67.3M | -CN¥66.7M | -CN¥102M | -CN¥319M | -CN¥14.9M |
| Capital expenditure | CN¥59.0M | CN¥73.8M | CN¥227M | CN¥368M | CN¥166M |
| Total debt | CN¥1.71B | CN¥1.82B | CN¥1.99B | CN¥1.95B | CN¥1.65B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002562.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.6% | -7.1% | 5th lowest of 21 |
| 6-month return | -28.4% | -17.2% | 5th lowest of 21 |
| Distance from 52-week high | -47.6% | -37.7% | 7th lowest of 21 |
| Revenue growth (TTM) | +7.8% | -4.2% | 6th highest of 20 |
| Operating margin | 4.0% | 9.5% | 8th lowest of 19 |
| EV / Sales | 1.6× | 3.4× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 4.9% | 4.0% | 6th most demanding of 12 |
| Growth delivered (Del g) | +13.5% | +8.9% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | -8.5 pp | -3.0 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | -0.2 pp | +0.1 pp | 9th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 5.1× | 4.0% | +18.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 5.0× | 25.8% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 3.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | n/a | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 1.0× | 1.5% | +7.9% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 5.1× | 14.1% | +62.3% |